首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1425117

異位性皮膚炎治療藥物市場－2024年至2029年預測

Atopic Dermatitis Drugs Market - Forecasts from 2024 to 2029

出版日期: 2024年01月24日 | 出版商:

Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計異位性皮膚炎治療藥物市場在預測期內將以 8.92% 的複合年成長率成長。

最常見的發炎皮膚病之一是異位性皮膚炎（AD）。雖然症狀因人而異，但 AD 的特徵是濕疹和皮膚搔癢。氣喘、食物過敏和結膜炎等眼科疾病只是 AD 相關併發症的一部分。外用皮質類固醇、Calcineurin抑制劑和生物製藥注射常用於治療 AD。

兒童異位性皮膚炎盛行率增加

異位性皮膚炎患者會因皮膚、上呼吸道和下呼吸道屏障受損而出現症狀。如果父母任何一方患有異位性皮膚炎，則他們的孩子也有 50% 的機會患有異位性皮膚炎。如果父母雙方都患有異位性皮膚炎，80%的孩子都會受到影響。基因變化包括表皮蛋白絲聚合蛋白（細絲聚集蛋白）的功能喪失突變，該蛋白被轉化為天然保濕因子。高達 30% 的異位性皮膚炎患者存在絲聚蛋白突變，這也使他們面臨過敏性鼻炎、尋常性魚鱗癬和毛周角化病的風險。

異位性皮膚炎增加

根據美國國家醫學圖書館的數據，在富裕國家，異位性皮膚炎影響2%至10%的成年人和10%至30%的兒童，這對異位性皮膚炎藥物產業產生了重大影響。近幾十年來，異位性皮膚炎的盛行率增加了兩到三倍。在高緯度地區，異位性皮膚炎的盛行率較高，這可能是由於陽光照射較少和濕度較低所致。異位性皮膚炎根據發病年齡分為三個亞組，但最常見的類型是早發性異位性皮膚炎（從出生到2歲），大約60%的病例發生在1歲之前。 60% 的病例到 12 歲時就會消退。遲發性異位性皮膚炎會導致青春期後出現症狀。老年性異位性皮膚炎是一種罕見的亞型，發生於 60 歲以上的成年人。

增加塗抹在皮膚上的藥物的使用

該藥物有多種規格，可作為乳膏、凝膠或軟膏塗布，促進了異位性皮膚炎藥物產業的發展。對於2歲以上的患者，可以選擇含有Calcineurin抑制劑的洗劑和軟膏。例子包括Tacrolimus（Protopic）和Pimecrolimus（Eridel）。使用這些藥物時應避免陽光直射。此外，食品藥物管理局要求某些產品帶有黑框警告，表明可能患有淋巴瘤。發出此警告是因為局部Calcineurin抑制劑使用者中出現了許多淋巴瘤病例。

新治療方法介紹

目前和過去的疾病嚴重程度和合併症在 AD 治療中發揮著重要作用。濕疹的發病很大程度受表皮屏障的影響。患者教育、潤膚治療和避免觸發因素都是初始治療的一部分。潤膚劑以及低效局部皮質類固醇 (TCS) 已被證明是有益的，可以降低 AD 的發生率。 2022 年 12 月 Locatinlimab 是一種創新的、針對患者的單株抗體治療方法，在研究期間以及治療結束後長達 20 週內，對中度至重度異位性皮膚炎患者顯示出良好的療效。這一開拓正在推動異位性皮膚炎治療市場的成長。

在北美，異位性皮膚炎治療市場預計將穩定成長。

北美異位性皮膚炎治療市場預計將因異位性皮膚炎盛行率的增加和該地區的研究措施而受到推動。例如，推出了一個全新的國家皮膚研究網路，稱為SkIN Canada（加拿大皮膚調查網路）。對患者、看護者和醫療保健專業人員重要的研究重點將影響研究領域並確保效用對患者照護的實用性。異位性皮膚炎綜合護理途徑(AD-ICP) 為AD 患者管理提供了一種多學科方法，結合了當前AD 治療的循證指南和基於日常臨床實踐的專家意見。我們正在努力彌合兩者之間的差距此外，ICP 有潛力透過結合許多指南介入措施和要素（包括品質保證和護理協調核算）來改善指南建議。

異位性皮膚炎的臨床試驗

2023年8月，領克藥業股份有限公司公佈了其LNK01001成人異位性皮膚炎（AD）II期臨床試驗的積極關鍵統計資料。
2023年8月，知名臨床階段生物製藥企業明輝藥業宣布，MH004乳膏治療輕中度異位性皮膚炎的第3期臨床研究成功入組首例患者。這一成就標誌著該公司為患有這種常見皮膚病的患者提供新的、尖端的治療選擇的努力的一個重大轉折點。

FDA核准異位性皮膚炎治療藥物

2022年6月，Dupixent（R）（通用名：dupilumab）被美國食品藥物管理局（FDA）核准用於治療6個月至5歲兒童無法透過局部用藥治療的中度至重度異位性皮膚炎處方藥。核准用於治療效果不充分或不建議的兒童。
據輝瑞稱，2022年1月，美國食品藥物管理局（FDA）批准CIBINQO（通用名：abrocitinib），一種每日一次口服Janus激酶1（JAK1）抑制劑，核准治療難治性疾病。患有中度至重度異位性皮膚炎（AD）的成人。
2022年1月，RINVOQ(R)（通用名： Upadacitinib ）是一種既往治療無效且用其他錠劑或注射劑（包括生物製藥）控制效果不佳的藥物，或者如果其他錠劑或已獲得FDA核准的美國食品藥物管理局(FDA) 用於治療成人和 12 歲及以上兒童的中度至重度異位性皮膚炎，不建議使用注射劑。

One of the most prevalent inflammatory skin disorders is atopic dermatitis (AD). Although it might manifest differently in each person, eczematous and itchy skin lesions are the hallmarks of AD. Asthma, food allergies, and ocular conditions including conjunctivitis are just a few of the comorbidities associated with AD. Topical corticosteroids, calcineurin inhibitors, and injectable biologic drugs are frequently used to treat AD.

Growing prevalence of offspring atopic dermatitis

Patients with the atopic triad experience symptoms as a result of compromised skin, upper respiratory, and lower respiratory tract barrier. There is a greater than 50% likelihood that if one parent has atopic dermatitis, so will their child. Up to 80% of the kids will be impacted if both parents are sick. Genetic changes include loss-of-function mutations in the epidermal protein filaggrin (Filament aggregation protein), which is converted to a natural moisturizing factor. Up to 30% of those with atopic dermatitis have filaggrin mutations, which can also put them at risk for allergic rhinitis, ichthyosis vulgaris, and keratosis pilaris.

Rising incidences of atopic dermatitis

According to the National Library of Medicine, in wealthy nations, 2% to 10% of adults and 10% to 30% of children are affected by atopic dermatitis which highly impacts the atopic dermatitis drugs industry. In recent decades, its incidence has climbed by two to three times. Greater latitudes have a greater prevalence of atopic dermatitis, which may be due to less sun exposure and less humidity. Based on the age of onset, atopic dermatitis is categorized into three subgroups, the most prevalent kind of atopic dermatitis, with around 60% of cases beginning before age 1, is early-onset atopic dermatitis (birth to two years old). 60% of cases are settled by the age of 12. Atopic dermatitis with a late start occurs when symptoms appear after puberty. Senile onset atopic dermatitis is an uncommon subtype that develops in adults beyond the age of 60.

Growth in the usage of medication applied to the skin

Various medications come in a range of strengths and can be applied as creams, gels, or ointments boosting the atopic dermatitis drugs industry. Calcineurin inhibitor-containing lotions or ointments may be an option for patients older than two. Examples include tacrolimus (Protopic) and pimecrolimus (Elidel). The patient must keep out of the direct sun while using these drugs. Additionally, the Food and Drug Administration is obligated to put a black box warning on certain products addressing the potential for lymphoma. This warning has been given because of a small number of cases of lymphoma among users of topical calcineurin inhibitors.

Introduction of new treatments

The severity of the illness, both currently and in the past, as well as comorbidities, have a significant role in AD care. The development of the eczema illness is significantly influenced by the epidermal barrier. Patient education, emollient treatment, and trigger avoidance are all part of the initial care. Emollients can be just as beneficial as topical corticosteroids (TCS) of low potency and have been shown to decrease the incidence of AD. In December 2022, the innovative, patient-tailored monoclonal antibody therapy rocatinlimab demonstrated excellent outcomes in patients with moderate to severe atopic dermatitis throughout the study and for up to 20 weeks after the treatment was terminated. This development is boosting the growth of the atopic dermatitis drug market.

In North America, it is projected that the atopic dermatitis drugs market will grow steadily.

The atopic dermatitis drug market in North America is anticipated to be fueled by the growing prevalence of atopic dermatitis and research initiatives in the region. For instance, a brand-new national skin research network called SkIN Canada (Skin Investigation Network of Canada) was introduced. Research priorities that are significant to patients, carers, and healthcare professionals are being established to influence the research landscape and guarantee its usefulness to patient care. By providing a coordinated multidisciplinary approach to patient management of AD, the integrated care pathways for atopic dermatitis (AD-ICPs) seek to close the gap between current AD treatment evidence-based guidelines and expert opinion based on everyday practice. Moreover, by combining interventions and elements from many guidelines, including quality assurance, and explaining care coordination, ICPs have the potential to improve guideline recommendations.

Atopic Dermatitis Clinical Trials

In August 2023, Positive topline statistics from the LNK01001 phase II clinical study for adults with atopic dermatitis (AD) were released by Lynk Pharmaceuticals Co., Ltd. Preliminary data after 12 weeks of therapy revealed that patients in the low-dose and high-dose groups significantly improved their Eczema Area and Severity Index (EASI) ratings from baseline compared to the placebo group.
In August 2023, the phase 3 clinical research for MH004 Cream, which targets mild to moderate atopic dermatitis, successfully enrolled its first patient, according to Minghui Pharmaceutical, Inc., a prominent clinical-stage biopharmaceutical business. This accomplishment represents a crucial turning point in the effort to provide patients suffering from this common skin ailment with new and cutting-edge therapeutic choices.

FDA Approvals for Atopic Dermatitis Drugs Drugs

In June 2022, Dupixent® (dupilumab) was authorized by the U.S. Food and Drug Administration (FDA) for use in children with moderate-to-severe atopic dermatitis who are 6 months to 5 years old and whose condition is not well managed by topical prescription medications or when such therapies are not recommended.
In January 2022, The U.S. Food and Drug Administration (FDA) has authorized CIBINQO® (abrocitinib), an oral, once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of adults with refractory, moderate-to-severe-atopic dermatitis (AD), according to Pfizer Inc.
In January 2022, RINVOQ® (upadacitinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to prior therapy and is not well controlled with other pills or injections, including biologic medications, or when use of other pills or injections is not advised.

Market Key Developments

In May 2023, according to the information from a new secondary analysis from Eli Lilly and Company's Phase 3 clinical development program patients receiving lebrikizumab who were evaluated at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body.
In June 2021, Amgen and Kyowa Kirin Co., Ltd. reached a deal to work together to develop and market KHK4083, a potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody that Kyowa Kirin is currently developing for the treatment of atopic dermatitis with potential for use in other autoimmune diseases.

Segmentation:

By Drug

Corticosteroids
Calcineurin Inhibitors
PDE4 Inhibitors
Biologics
Others

By Route of Administration

Topical
Injectable
Oral

By End-User

Hospitals
Clinics
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. ATOPIC DERMATITIS DRUGS MARKET, BY DRUG

5.1. Introduction
5.2. Corticosteroids
5.3. Calcineurin Inhibitors
5.4. PDE4 Inhibitors
5.5. Biologics
5.6. Others

6. ATOPIC DERMATITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

6.1. Introduction
6.2. Topical
6.3. Injectable
6.4. Oral

7. ATOPIC DERMATITIS DRUGS MARKET, BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Others

8. ATOPIC DERMATITIS DRUGS MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others